Viatris posted flat revenue in Q3 2025, with a net loss of $128 million primarily due to a decline in the fair value of Biocon Biologics shares and higher tax expense. Despite this, the company maintained strong adjusted profitability and raised full-year guidance.
Total revenue for Q3 2025 was $3.76 billion, flat compared to the prior year.
Reported net loss of $128 million due to fair value reduction of Biocon Biologics investment and tax increase.
Adjusted EBITDA was $1.15 billion and adjusted EPS was $0.67.
Raised full-year 2025 guidance for revenue, adjusted EBITDA, and adjusted EPS.
Viatris raised and narrowed its 2025 guidance ranges, reflecting FX tailwinds and strong execution. The company now projects revenue between $13.9B and $14.3B, adjusted EBITDA between $4.0B and $4.2B, and adjusted EPS between $2.25 and $2.35.
Visualization of income flow from segment revenue to net income